TW262385B - - Google Patents

Info

Publication number
TW262385B
TW262385B TW082100284A TW82100284A TW262385B TW 262385 B TW262385 B TW 262385B TW 082100284 A TW082100284 A TW 082100284A TW 82100284 A TW82100284 A TW 82100284A TW 262385 B TW262385 B TW 262385B
Authority
TW
Taiwan
Application number
TW082100284A
Other languages
Chinese (zh)
Original Assignee
Cygnus Therapeutic Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cygnus Therapeutic Systems filed Critical Cygnus Therapeutic Systems
Application granted granted Critical
Publication of TW262385B publication Critical patent/TW262385B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
TW082100284A 1991-12-20 1993-01-18 TW262385B (2)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/810,963 US5229130A (en) 1991-12-20 1991-12-20 Vegetable oil-based skin permeation enhancer compositions, and associated methods and systems

Publications (1)

Publication Number Publication Date
TW262385B true TW262385B (2) 1995-11-11

Family

ID=25205155

Family Applications (1)

Application Number Title Priority Date Filing Date
TW082100284A TW262385B (2) 1991-12-20 1993-01-18

Country Status (7)

Country Link
US (1) US5229130A (2)
EP (1) EP0617600A4 (2)
JP (1) JP3026602B2 (2)
AU (1) AU3247293A (2)
CA (1) CA2126214A1 (2)
TW (1) TW262385B (2)
WO (1) WO1993012744A1 (2)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5460821A (en) * 1993-06-23 1995-10-24 Masiz; John J. Molecular transdermal transport system
US5645854A (en) * 1993-06-23 1997-07-08 Masiz; John J. Molecular transdermal transport system
WO1995000088A1 (en) * 1993-06-23 1995-01-05 Masiz John J Molecular transdermal transport system
US5853751A (en) * 1993-06-23 1998-12-29 Masiz; John J. Molecular transdermal transport system
US5627216A (en) * 1994-02-07 1997-05-06 Papadopoulos; George D. Medicinal ointment for hemorrhoid and skin care
DE4407742C1 (de) * 1994-03-08 1995-06-22 Hexal Pharma Gmbh Transdermales System in Form eines Pflasters mit einem Tamoxifen-Derivat
US5516517A (en) * 1994-05-02 1996-05-14 Exfoliation Cleansing Hydration Oxygenation Corporation Method for nutritional oxygenation of the skin
US5849729A (en) * 1995-12-26 1998-12-15 Hershey Foods Corporation Use of hydrolyzed cocoa butter for percutaneous absorption
US5837227A (en) * 1995-12-26 1998-11-17 Hershey Foods Corporation Use of cocoa butter or partially hydrolyzed cocoa butter for the treatment of burns and wounds
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
IT1294748B1 (it) * 1997-09-17 1999-04-12 Permatec Tech Ag Formulazione per un dispositivo transdermico
US6423334B1 (en) * 1997-10-01 2002-07-23 Elan Corporation, Plc Composition and method for enhancing transport across gastrointestinal tract cell layers
CA2225352C (en) * 1998-01-30 2003-10-21 Nam Fong Han Vegetable derived petroleum jelly replacement
GB2344520A (en) * 1998-12-08 2000-06-14 Phares Pharm Res Nv Pharmaceutical carriers comprising lipids and polymers
US6093417A (en) * 1999-01-11 2000-07-25 Advanced Medical Instruments Composition to treat ear disorders
US6552024B1 (en) 1999-01-21 2003-04-22 Lavipharm Laboratories Inc. Compositions and methods for mucosal delivery
US20070148228A1 (en) * 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
US8119159B2 (en) * 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
US6399093B1 (en) 1999-05-19 2002-06-04 Advanced Medical Instruments Method and composition to treat musculoskeletal disorders
DE19927229B4 (de) * 1999-06-10 2004-09-09 Coty B.V. Enzymhaltiges Kosmetikum und dessen Verwendung
US6573299B1 (en) 1999-09-20 2003-06-03 Advanced Medical Instruments Method and compositions for treatment of the aging eye
US6455066B1 (en) 2000-03-10 2002-09-24 Epicept Corporation Intradermal-penetration agents for topical local anesthetic administration
US6635274B1 (en) * 2000-10-27 2003-10-21 Biochemics, Inc. Solution-based transdermal drug delivery system
EP1390383B1 (en) * 2001-05-11 2012-02-29 Isis Pharmaceuticals, Inc. Antisense permeation enhancers
WO2002092070A1 (en) * 2001-05-11 2002-11-21 Elan Corporation, Plc Isostearic acid salts as permeation enhancers
US6559182B1 (en) * 2001-11-07 2003-05-06 Purcell Jojoba International, Llc Method for treatment of enveloped viruses using jojoba oil esters
US20040033253A1 (en) * 2002-02-19 2004-02-19 Ihor Shevchuk Acyl opioid antagonists
CA2477120C (en) * 2002-03-06 2011-06-14 Hexal Ag Transdermal system with fentanyl
JP4302534B2 (ja) * 2002-04-15 2009-07-29 哲夫 山東 皮膚炎治療用ローション
WO2003086433A1 (en) * 2002-04-15 2003-10-23 Tetsuo Santo Therapeutic cream for dermatitis
EP1513532B1 (en) 2002-06-10 2007-02-28 Euro-Celtique S.A. Disposal systems of transdermal delivery devices to prevent misuse of the active agents contained therein
DK1530469T3 (da) * 2002-08-20 2009-05-04 Euro Celtique Sa Transdermal dosisform omfattende et aktivt middel og et salt og fri baseform af en antagonist
US20040258740A1 (en) * 2003-04-10 2004-12-23 Nene Labs Transdermal delivery composition
US20080020028A1 (en) * 2003-08-20 2008-01-24 Euro-Celtique S.A. Transdermal dosage form comprising an active agent and a salt and a free-base form of an adverse agent
US20060233739A1 (en) * 2003-11-24 2006-10-19 Thornfeldt Carl R Treatment of mucocutaneous disorders through reversing chronic imflammation and barrier disruption
US8252320B2 (en) 2004-10-21 2012-08-28 Durect Corporation Transdermal delivery system for sufentanil
US8246977B2 (en) 2004-10-21 2012-08-21 Durect Corporation Transdermal delivery systems
US8258305B2 (en) 2005-02-23 2012-09-04 Prexa Pharmaceuticals, Inc. Dopamine transporter inhibitors for use in treatment of movement disorders and other CNS indications
US20070087055A1 (en) * 2005-10-14 2007-04-19 David Jan Directly compressible extended release alprazolam formulation
KR101191322B1 (ko) * 2006-04-07 2012-10-16 메리온 리서치 Ⅲ 리미티드 증진제를 함유하는 고형 경구용 투여 제형
EP2040731A4 (en) * 2006-06-09 2010-05-19 Merrion Res Iii Ltd SOLID DOSAGE FORM FOR ORAL ADMINISTRATION CONTAINING AN ACTIVATOR
US7282225B1 (en) 2006-09-27 2007-10-16 Occular Technologies, Inc. Composition and methods for improving retinal health
DE102006048130A1 (de) * 2006-10-06 2008-04-10 Axxonis Pharma Ag Transdermales therapeutisches System mit zweiphasigem Freisetzungsprofil
US20080152592A1 (en) * 2006-12-21 2008-06-26 Bayer Healthcare Llc Method of therapeutic drug monitoring
US20080227805A1 (en) 2007-02-28 2008-09-18 Abbott Laboratories Sustained release parenteral formulations of buprenorphine
US20080226698A1 (en) * 2007-03-16 2008-09-18 Mylan Technologies, Inc. Amorphous drug transdermal systems, manufacturing methods, and stabilization
WO2008115224A2 (en) * 2007-03-20 2008-09-25 Bayer Healthcare Llc Method of analyzing an analyte
US20090142528A1 (en) 2007-08-18 2009-06-04 Earth First Industries Incorporated Composites for packaging articles and method of making same
US20090111780A1 (en) * 2007-10-31 2009-04-30 Everett Laboratories, Inc. Compositions and methods for treatment of ear canal infection and inflammation
US20090123504A1 (en) * 2007-11-12 2009-05-14 Kimberly-Clark Worldwide, Inc. Olive oil formulation for pain relief
US20090130048A1 (en) * 2007-11-19 2009-05-21 Oronsky Bryan Todd Topical Composition for Treating Pain
US20090227461A1 (en) * 2008-03-06 2009-09-10 Roberto Carpentier Preventing and/or Reducing "Lenticel Breakdown" Physiological Disorder in Apples by Applying Pre-Harvest Coatings
CA2719637C (en) 2008-03-27 2014-10-28 Agigma, Inc. Methods and compositions for the delivery of agents
CN107096012A (zh) * 2008-05-07 2017-08-29 诺和诺德股份有限公司 肽的组合物及其制备方法
EP2307001A1 (en) * 2008-06-11 2011-04-13 BioChemics, Inc. Control of blood vessel physiology to treat skin disorders
US8592424B2 (en) 2008-06-30 2013-11-26 Afgin Pharma Llc Topical regional neuro-affective therapy
CA2749941C (en) 2008-09-10 2018-04-24 Biochemics, Inc. Ibuprofen for topical administration
MX349176B (es) * 2008-09-22 2017-07-14 Biochemics Inc Suministro transdermico de farmaco empleando un osmolito y un agente vasoactivo.
EP2349230A2 (en) 2008-10-06 2011-08-03 Mylan Technologies, Inc. Amorphous rotigotine transdermal system
US9278233B2 (en) * 2008-12-04 2016-03-08 Biochemics, Inc. Methods and compositions for tattoo removal
AU2010203223B9 (en) 2009-01-05 2015-10-08 Epitogenesis Inc. Adjuvant compositions and methods of use
US20100215743A1 (en) * 2009-02-25 2010-08-26 Leonard Thomas W Composition and drug delivery of bisphosphonates
DE102009013469B4 (de) 2009-03-19 2014-04-17 Bubbles And Beyond Gmbh Zubereitung zur äußerlichen Anwendung
US20110182985A1 (en) * 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
US8685472B2 (en) 2010-03-01 2014-04-01 Access Business Group International Llc Skin whitening composition containing chia seed extract
WO2011120033A1 (en) * 2010-03-26 2011-09-29 Merrion Research Iii Limited Pharmaceutical compositions of selective factor xa inhibitors for oral administration
WO2012050763A2 (en) 2010-09-29 2012-04-19 Access Business Group International Llc Chia seed extract and related method of manufacture
EP2661273A4 (en) 2011-01-07 2014-06-04 Merrion Res Iii Ltd IRON PHARMACEUTICAL COMPOSITIONS FOR ORAL ADMINISTRATION
CA2826003C (en) * 2011-02-02 2019-01-08 Yasuaki Okada Blonanserin-containing patch preparation
WO2012105624A1 (ja) * 2011-02-02 2012-08-09 大日本住友製薬株式会社 経皮吸収用貼付製剤
CN107837394A (zh) 2011-06-24 2018-03-27 埃皮托吉尼西斯有限公司 作为抗原特异性免疫调节剂的包含选择的载体、维生素、单宁和类黄酮的组合的药物组合物
DE102012000369A1 (de) * 2012-01-11 2013-07-11 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermales therapeutisches System mit Cholinesterase-Hemmer
US10471131B2 (en) 2012-01-19 2019-11-12 Hybrid Medical, Llc Topical therapeutic formulations
EP3269372B1 (en) 2012-01-19 2019-06-12 Hybrid Medical, LLC Topical therapeutic formulations
US20160101114A1 (en) * 2013-03-25 2016-04-14 Sloan-Kettering Institute For Cancer Research Articles and methods for preventing and treating dermatologic adverse events
JP6564369B2 (ja) 2013-12-09 2019-08-21 デュレクト コーポレイション 薬学的活性剤複合体、ポリマー複合体、ならびにこれらを伴う組成物及び方法
WO2016027216A2 (en) * 2014-08-22 2016-02-25 Venna Gopal A synergistic edible oil composition
US10265384B2 (en) 2015-01-29 2019-04-23 Novo Nordisk A/S Tablets comprising GLP-1 agonist and enteric coating
GB2537647A (en) * 2015-04-22 2016-10-26 Cosmetic Warriors Ltd Composition
JP7325792B2 (ja) * 2017-06-30 2023-08-15 三省製薬株式会社 皮膚透過性促進剤および皮膚外用剤
RU2697411C2 (ru) * 2017-10-11 2019-08-14 федеральное государственное автономное образовательное учреждение высшего образования Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский университет) Композиция для лечения болезни Паркинсона
RU2020130919A (ru) * 2018-03-29 2022-04-29 Лумоса Терапьютикс Ко., Лтд. Композиции и способы для лечения зуда
JP7089603B2 (ja) 2018-06-11 2022-06-22 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 眼疾患を治療するための脱メチル化
WO2020237244A1 (en) * 2019-05-23 2020-11-26 Professional Compounding Centers Of America, Inc. Skin permeation enhancing composition

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3551554A (en) * 1968-08-16 1970-12-29 Crown Zellerbach Corp Enhancing tissue penetration of physiologically active agents with dmso
US3472931A (en) * 1969-01-17 1969-10-14 Foster Milburn Co Percutaneous absorption with lower alkyl amides
DE2446162A1 (de) * 1974-09-27 1976-04-15 Schlafhorst & Co W Verfahren und vorrichtung zum zufuehren leerer konischer spulenhuelsen zu den einzelnen spulstellen einer textilmaschine
US4316893A (en) * 1975-06-19 1982-02-23 Nelson Research & Development Co. Vehicle composition containing 1-substituted azacycloalkan-2-ones
US4405616A (en) * 1975-06-19 1983-09-20 Nelson Research & Development Company Penetration enhancers for transdermal drug delivery of systemic agents
US3989816A (en) * 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
CA1165240A (en) * 1980-07-09 1984-04-10 The Procter & Gamble Company Penetrating topical pharmaceutical compositions
US4379454A (en) * 1981-02-17 1983-04-12 Alza Corporation Dosage for coadministering drug and percutaneous absorption enhancer
US4440777A (en) * 1981-07-07 1984-04-03 Merck & Co., Inc. Use of eucalyptol for enhancing skin permeation of bio-affecting agents
US4537776A (en) * 1983-06-21 1985-08-27 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing N-(2-hydroxyethyl) pyrrolidone
US4557934A (en) * 1983-06-21 1985-12-10 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one
US4552872A (en) * 1983-06-21 1985-11-12 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing corticosteroids
JPS60174716A (ja) * 1984-02-21 1985-09-09 Yamanouchi Pharmaceut Co Ltd パツチ剤
US4626539A (en) * 1984-08-10 1986-12-02 E. I. Dupont De Nemours And Company Trandermal delivery of opioids
US4568343A (en) * 1984-10-09 1986-02-04 Alza Corporation Skin permeation enhancer compositions
US4908389A (en) * 1986-08-27 1990-03-13 Warner-Lambert Company Penetration enhancement system
EP0272336B1 (de) * 1986-12-18 1991-10-23 Kurt H. Prof. Dr. Bauer Gegenüber Lichteinfluss stabilisiertes Nifedipin-Konzentrat und Verfahren zu seiner Herstellung
AU601528B2 (en) * 1986-12-22 1990-09-13 Ortho-Mcneil Pharmaceutical, Inc. Resilient transdermal drug-delivery device and compositions and devices employing fatty acid esters/ethers of alkanediols and percutaneous absorption enhancers
US4746515A (en) * 1987-02-26 1988-05-24 Alza Corporation Skin permeation enhancer compositions using glycerol monolaurate
US4900555A (en) * 1987-02-26 1990-02-13 Alza Corporation Skin permeation enhancer compositions using sucrose esters
CH674618A5 (2) * 1987-04-02 1990-06-29 Ciba Geigy Ag
US4783450A (en) * 1987-04-13 1988-11-08 Warner-Lambert Company Use of commercial lecithin as skin penetration enhancer
US4764379A (en) * 1987-08-24 1988-08-16 Alza Corporation Transdermal drug delivery device with dual permeation enhancers
US5019395A (en) * 1988-03-08 1991-05-28 Warner-Lambert Company Compositions with enhanced penetration
US4973468A (en) * 1989-03-22 1990-11-27 Cygnus Research Corporation Skin permeation enhancer compositions
US5225198A (en) * 1991-08-27 1993-07-06 Cygnus Therapeutic Systems Transdermal administration of short or intermediate half-life benzodiazepines
BR9200386A (pt) * 1992-01-30 1992-07-07 Giuseppe Betti Emulsao veicular basica

Also Published As

Publication number Publication date
JP3026602B2 (ja) 2000-03-27
US5229130A (en) 1993-07-20
EP0617600A1 (en) 1994-10-05
WO1993012744A1 (en) 1993-07-08
CA2126214A1 (en) 1993-07-08
AU3247293A (en) 1993-07-28
EP0617600A4 (en) 1995-06-14
JPH07506562A (ja) 1995-07-20

Similar Documents

Publication Publication Date Title
TW262385B (2)
TW278069B (2)
DE4290891T1 (2)
FR2675558B1 (2)
EP0512438A3 (2)
DK0539725T3 (2)
DK0511526T3 (2)
TW221422B (2)
ATA181891A (2)
DE4290105T1 (2)
JPH0496061U (2)
DK0545490T3 (2)
JPH0499459U (2)
JPH0498829U (2)
JPH0498329U (2)
ECSM91561U (2)
DK132791D0 (2)
IN184665B (2)
IN174514B (2)
ECSDI910049S (2)
ECSDI910041S (2)
ECSM91556U (2)
ECSM91533U (2)
JPH0498702U (2)
GB9113147D0 (2)